Understanding the tumor suppressor activities of ATRX-DAXX through epigenomic profiling and animal models

Understanding the physiologically relevant functions of Daxx

Understanding the genetic and cellular origins of carcinoid cancer

Tumor-Specific Delivery of Temozolomide to Overcome Resistance in GEP-NET

Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids

Trends in Incidence and Survival Outcomes for Lung Neuroendocrine Tumors

Transcriptome and methylome of pancreatic NETs with and without ATRX/DAXX mutations

To identify mechanism of resistance and therapeutic strategies to overcome resistance to currently available mTOR inhibitors

The role of the B7x pathway in the progression of neuroendocrine tumors

The impact of MEN1, DAXX, ATRX, and PTEN in pancreatic neuroendocrine cancer pathogenesis

Targeting angiopoietin-2 to improve ICI therapy efficacy in pNET metastasis

Target Neuron-Cancer Interactions in NETs by Non-Invasive Imaging of SV2A

Studying field cancerization as a cause for multifocal ileal NETs

Simultaneous Auger-e- and ß–Particle therapy of metastasized NET using 161Tb-DOTATOC

Role of CCL2 and IL-8 in pituitary neuroendocrine tumor microenvironment

Role of ATRX/DAXX/H3.3 Chromatin Regulation in Pancreatic NETs

PRESCIENT – PET REsponSe CrItEria for Neuroendocrine Tumors

Phase I/II Study of Intratumoral Ipilimumab with Anti-PD-L1 in Patients with Advanced, Progressive, Well-Differentiated NETS

Pancreatic neuroendocrine tumors (NETs), are rare morphologically well-differentiated malignancies with an unacceptably poor 5-year survival rate of 20%. Multiple lines of evidence suggest that immunosuppressive Tregs play a critical role in preventi

Overcoming Resistance to mTOR Inhibition in pancreatic NETs

Origin and differentiation of a new class of serotonin-expressing enteroendocrine cells

Novel radioligands to improve radiotherapy of neuroendocrine tumors

Novel Antibody-Drug Conjugate for PancreaticNET Targeted Therapy

New Strategies to Improve Drug Development Specific to Carcinoid Tumors

Neoantigen-reactive T cells for personalized treatment of panNETs

NANETs: Deciphering and potentiating intrinsic radiosensitivity of Pancreatic Neuroendocrine Tumors

Mutational landscape of pancreatic NETs – Using the “liquid biopsy” to study genetic evolution over time and through therapy

Multipronged approaches to develop immunotherapy targeting NETs

Multifunctional nanomedicine for targeted carcinoid cancer therapy

Multidimensional immune profiling of advanced pancreatic NETs

Molecular Influences of Racial Disparities in Pancreatic Neuroendocrine Tumors

Molecular events underlying development and progression of DIPNECH

Molecular analysis of the immune environment of neuroendocrine tumors and associations with clinical outcomes

Mesenteric fibrosis in small intestinal neuroendocrine tumors: pathogenesis

Investigating PanNET tumorigenesis with single cell genomics

Identifying altered epigenetic states and drivers in intestinal carcinoid and pancreatic NETs

Identify and validate molecular targets for therapy in a newly developed human midgut carcinoid tumor cell line

Hypoxia onco-metabolic drivers in pancreatic and small-intestine NET

Functionalized Silica Nanoparticles: Development of a Combined PET and TAT Theranostic Agent for NETs

Fluorine-18 Labeled MIBG Analogues for Theranostic Applications

Finding the causes of small intestinal neuroendocrine tumors.

Exploring the role of epigenetic dysregulation in PanNET progression

Ex vivo compound prioritization for gastroenteropancreatic NETs

Evaluation of 225Ac-DOTATATE for treatment of lung carcinoid tumors

Establishment and genome characterization of PNET mouse models

ERF: Uncovering the cellular mechanisms that limit clinical application of PRRT

ERF: Targeted alpha therapy of NETs using somatostin-based radiopharmaceuticals with improved tumor-to-kidney ratio, the theranostic approach

Epigenomic analysis of intestinal neuroendocrine cells and the epigenetic basis of NETs

Epigenetic Regulators of Intestinal Endocrine Cells and Carcinoid Tumors*

Epigenetic Dysregulation of Transposons in Pancreatic Neuroendocrine Tumors

Enlightenment of a new era of cancer therapy: prognostication, target selection, and subsequent therapy determined by the dual tumor-immune phenotype

Enhancing somatostatin agonist radionuclide therapy in GEP-NETs

Enhancing Peptide Receptor Radionuclide Therapy in Well-Differentiated Pancreatic NETs

Emergence of high-grade and treatment-resistant pancreatic NET subclones

Elucidate the role of the MEN1 gene in carcinoid tumors and determine a functional connection between the genes MEN1, Rbp2 and p27

Elucidate the Developmental and Regulatory Heterogeneity of Lung Carcinoids

Dissecting the ecosystem of neuroendocrine tumors by single cell genomics

Discovering new inhibitors of pancreatic NET glucose consumption

Discover new treatments for carcinoid cancer and pancreatic neuroendocrine cancer

Developmental Lineages and Microenvironmental Heterogeneity in PNETs

Development of In Vitro and In Vivo Preclinical Models for Small Bowel NET*

Development of ex-vivo models of metastatic neuroendocrine tumors

Developing novel treatments for NETs using CAR T-Cell Technology

Determining whether there are unique protein expression patterns in gastrointestinal NETs

Defining the immune landscape of NETs – towards rational combination therapy

Defining Distinct Subtypes of NECs to Predict Therapeutic Vulnerabilities

Comprehensive molecular characterisation of lung supra-carcinoids

Collaborative Award: Treating neuroendocrine tumors via synthetic lethality

Collaborative Award: Targeting the Alternative Lengthening of Telomere (ALT) pathway in pancreatic NETs

Collaborative Award: Intra-arterial Peptide Receptor Radionuclide Therapy (IA-PRRT) using 90Y-DOTA-TOC

Collaborative Award : Implication of heterogeneous innate immune cells in pancreatic NET resistance

Collaborative Award -Octreotide-targeted treatment of pancreatic NETs

Cellular Reprogramming of Enteroendocrine Cells and Neuroendocrine Tumors

Biomarkers of response to cabozantinib in patients with neuroendocrine tumors

Angiopoietin-2/Tie2 signaling regulation of liver metastasis in PNETs

An integrated preclinical and clinical evaluation of DNA-repair mechanisms in determining response to PRRT as a guide to patient selection and for development of novel combination therapies

An Improved Approach for Detection and Therapeutic Monitoring of NETs by PET

Alternative Splicing in PNET: an unexplored source of therapeutic targets

A phenotypically valid model for SDHB-mutated paraganglioma

A Human Pluripotent Stem Cell-based Model for Lung Carcinoid